Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $288.67 million. The enterprise value is $238.07 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, after market close.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 227.30 million shares outstanding. The number of shares has increased by 22.21% in one year.
Current Share Class | 227.30M |
Shares Outstanding | 227.30M |
Shares Change (YoY) | +22.21% |
Shares Change (QoQ) | +0.09% |
Owned by Insiders (%) | 3.13% |
Owned by Institutions (%) | 58.88% |
Float | 183.75M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.35 |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | 32.28 |
P/OCF Ratio | 32.19 |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.91 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 26.21 |
Financial Position
The company has a current ratio of 5.71
Current Ratio | 5.71 |
Quick Ratio | 5.49 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | 22.32 |
Interest Coverage | -4.92 |
Financial Efficiency
Return on equity (ROE) is -500.57% and return on invested capital (ROIC) is -15.84%.
Return on Equity (ROE) | -500.57% |
Return on Assets (ROA) | -12.68% |
Return on Invested Capital (ROIC) | -15.84% |
Return on Capital Employed (ROCE) | -23.57% |
Revenue Per Employee | $859,241 |
Profits Per Employee | -$353,366 |
Employee Count | 145 |
Asset Turnover | 0.46 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Gossamer Bio has paid $893,000 in taxes.
Income Tax | 893,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +148.82% in the last 52 weeks. The beta is 1.85, so Gossamer Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.85 |
52-Week Price Change | +148.82% |
50-Day Moving Average | 1.05 |
200-Day Moving Average | 1.00 |
Relative Strength Index (RSI) | 58.64 |
Average Volume (20 Days) | 1,520,466 |
Short Selling Information
The latest short interest is 11.08 million, so 4.88% of the outstanding shares have been sold short.
Short Interest | 11.08M |
Short Previous Month | 10.54M |
Short % of Shares Out | 4.88% |
Short % of Float | 6.03% |
Short Ratio (days to cover) | 6.71 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $124.59 million and -$51.24 million in losses. Loss per share was -$0.23.
Revenue | 124.59M |
Gross Profit | 124.59M |
Operating Income | -54.77M |
Pretax Income | -172.58M |
Net Income | -51.24M |
EBITDA | -54.19M |
EBIT | -54.77M |
Loss Per Share | -$0.23 |
Full Income Statement Balance Sheet
The company has $257.93 million in cash and $202.79 million in debt, giving a net cash position of $55.15 million or $0.24 per share.
Cash & Cash Equivalents | 257.93M |
Total Debt | 202.79M |
Net Cash | 55.15M |
Net Cash Per Share | $0.24 |
Equity (Book Value) | -6.25M |
Book Value Per Share | -0.03 |
Working Capital | 227.25M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $9.11 million and capital expenditures -$26,000, giving a free cash flow of $9.08 million.
Operating Cash Flow | 9.11M |
Capital Expenditures | -26,000 |
Free Cash Flow | 9.08M |
FCF Per Share | $0.04 |
Full Cash Flow Statement Margins
Gross margin is 100.00%, with operating and profit margins of -43.96% and -41.13%.
Gross Margin | 100.00% |
Operating Margin | -43.96% |
Pretax Margin | -40.41% |
Profit Margin | -41.13% |
EBITDA Margin | -43.49% |
EBIT Margin | -43.96% |
FCF Margin | 7.29% |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.21% |
Shareholder Yield | -22.21% |
Earnings Yield | -17.47% |
FCF Yield | 3.10% |
Analyst Forecast
The average price target for Gossamer Bio is $7.75, which is 510.24% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $7.75 |
Price Target Difference | 510.24% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | 25.76% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -5.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -5.3 |
Piotroski F-Score | 2 |